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M A J O R A R T I C L E
Recurrence due to Relapse or Reinfection With
Mycobacterium tuberculosis: A Whole-Genome
Sequencing Approach in a Large, Population-
Based Cohort With a High HIV Infection
Prevalence and Active Follow-up
José Afonso Guerra-Assunção,1 Rein M. G. J. Houben,1 Amelia C. Crampin,1,2 Themba Mzembe,2 Kim Mallard,3
Francesc Coll,3 Palwasha Khan,1 Louis Banda,2 Arthur Chiwaya,2 Rui P. A. Pereira,3 Ruth McNerney,3 David Harris,4
Julian Parkhill,4 Taane G. Clark,1,3 and Judith R. Glynn1
1Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, 2Karonga Prevention Study, Malawi, 3Faculty of
Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, and 4Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Background. Recurrent tuberculosis is a major health burden and may be due to relapse with the original strain
or reinfection with a new strain.
Methods. In a population-based study in northern Malawi, patients with tuberculosis diagnosed from 1996 to
2010 were actively followed after the end of treatment. Whole-genome sequencing with approximately 100-fold cov-
erage was performed on all available cultures. Results of IS6110 restriction fragment-length polymorphism analyses
were available for cultures performed up to 2008.
Results. Based on our data, a difference of ≤10 single-nucleotide polymorphisms (SNPs) was used to deﬁne re-
lapse, and a difference of >100 SNPs was used to deﬁne reinfection. There was no evidence of mixed infections
among those classiﬁed as reinfections. Of 1471 patients, 139 had laboratory-conﬁrmed recurrences: 55 had relapse,
and 20 had reinfection; for 64 type of recurrence was unclassiﬁed. Almost all relapses occurred in the ﬁrst 2 years.
Human immunodeﬁciency virus infection was associated with reinfection but not relapse. Relapses were associated
with isoniazid resistance, treatment before 2007, and lineage-3 strains. We identiﬁed several gene variants associated
with relapse. Lineage-2 (Beijing) was overrepresented and lineage-1 underrepresented among the reinfecting strains
(P = .004).
Conclusions. While some of the factors determining recurrence depend on the patient and their treatment, dif-
ferences in the Mycobacterium tuberculosis genome appear to have a role in both relapse and reinfection.
Keywords. tuberculosis; relapse; reinfection; HIV; whole-genome sequence; RFLP; recurrence.
Recurrent tuberculosis adds considerably to the burden
of tuberculosis [1]. It arises through relapse of the orig-
inal infection or through reinfection with a new strain.
The 2 mechanisms have different implications for the
patient and the control program. High rates of relapse
may indicate unsuccessful treatment (relapse usually
occurs early after the end of treatment and is associated
with cavitary disease and drug resistance) [2–4]. A high
rate of recurrence due to reinfection suggests a failure to
develop protective immunity after the ﬁrst episode and
is associated with human immunodeﬁciency virus
(HIV) infection [2, 3, 5].
Distinguishing the 2 mechanisms requires molecular
marker analysis of cultures from both episodes, so re-
sults are available from only a few studies. These have
shown varying proportions of disease due to reinfection
[6–8], from <3% [9] to >60% [10, 11]. High proportions
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of apparent reinfections may be due to mislabeling, to cross-
contamination or mixed infections, or to differences in patient
populations, length of follow-up [7], and background risk of
infection with Mycobacterium tuberculosis. A high proportion
of apparent relapses could indicate insufﬁcient variability of
strains in the population with the marker used. Most studies
to date have used IS6110-based restriction fragment-length
polymorphism (RFLP) analysis or mycobacterial interspersed
repetitive unit–variable number of tandem repeat (MIRU-
VNTR) typing [12].
Whole-genome sequencing gives greater discrimination than
RFLP analysis or MIRU-VNTR analysis, which should improve
the ability to distinguish relapse from reinfection. The one study
to date that evaluated whole-genome sequencing for this pur-
pose compared whole-genome sequencing data to MIRU-
VNTR data, resulting in reclassiﬁcation of several strains and
allowing detection of mixed infections [12]. Whole-genome se-
quencing also allows genetic determinants of recurrence to be
examined.
In a long-term population-based study of tuberculosis in
northern Malawi with active follow-up beyond the end of treat-
ment, we previously analyzed RFLP data from 1996 to 2005 and
found that HIV infection increased the risk of recurrence due to
reinfection but not the risk due to relapse [2]. Here, we have now
used whole-genome sequences of all available strains obtained
from patients up to 2010, and assessed the effect of HIV, M. tu-
berculosis lineage [13], and other factors on the rate of recur-
rence due to reinfection or relapse.
METHODS
Setting and Patients
The Karonga Prevention Study has been studying tuberculosis
in the whole of Karonga district, northern Malawi, since 1986
[14, 15]. The area is largely rural, with a population of around
300 000 and a prevalence of HIV infection among adults of
about 10%. Individuals with tuberculosis are identiﬁed through
enhanced passive surveillance, with project staff based at health
centers to identify those with chronic cough. Sputum and other
specimens (eg, lymph node aspirates) are processed in the pro-
ject laboratory. Cultures that appear to be positive for M. tuber-
culosis are sent to the United Kingdom for species conﬁrmation
and drug resistance testing, initially for resistance to isoniazid
and rifampicin and, if resistant to these, then for resistance to
further drugs. At least 3 sputum samples are obtained at the
time of diagnosis, with further samples collected at 2 months
and at the end of treatment.
Ethics approval for the study was given by the ethics commit-
tee of the London School of Hygiene and Tropical Medicine
and the Malawian National Health Science Research Commit-
tee. Informed consent was sought from each participant.
The incidence of smear-positive tuberculosis in adults in this
district peaked at 125 cases/100 000 in the mid 1990s and then
fell to 80–90 cases/100 000 [15]. The annual risk of infection
with M. tuberculosis in the 1980s and 1990s was estimated to
be 1% per year [14]. Since 1988, HIV testing has been offered
to all patients with tuberculosis, following counseling and con-
sent; nearly two thirds are HIV positive. Free antiretroviral ther-
apy (ART) has been available in the district since 2005 to
individuals with World Health Organization stage 3 or 4 disease
(which includes tuberculosis) or with CD4+ T-cell counts of
<250 cells/mL.
Patients are treated according to Malawi government guide-
lines. Beginning in 1996, new smear-positive patients received a
2-month course of treatment with streptomycin, isoniazid, ri-
fampicin, and pyrazinamide (2SHRZ) and a 6-month regimen
of ethambutol and isoniazid (6HE) therapy. Ethambutol re-
placed streptomycin beginning in 2001. New smear-negative
patients were treated with 1SEH/11HE until 2001, after which
treatment was the same as that for smear-positive patients.
Since January 2007, a 6-month regimen involving rifampicin
throughout has been used for all new patients (2HRZE/4HR).
Beginning in 1996, individuals requiring retreatment received
a regimen containing rifampicin throughout [15].
Individuals were deﬁned as having laboratory-conﬁrmed
tuberculosis if they had positive smears (excluding those
with single scanty smears) or M. tuberculosis–positive cultures
or histological evidence of tuberculosis. Outcomes beyond the
end of treatment were ascertained by linkage to our other stud-
ies in the district and by home visits in 2005 to those whose
vital status was unknown [16]. Since 2007 all patients have
been visited annually, with sputum specimens collected from
those who are symptomatic. Recurrences were deﬁned as fur-
ther episodes of diagnosed tuberculosis after the end of treat-
ment, whether or not there was microbiological evidence of
cure of the previous episode. Recurrences could be laboratory
conﬁrmed or not.
Molecular Methods
From 1996 to 2008, IS6110 RFLP analysis was done on all cul-
tures [17, 18]. Whole-genome sequencing was carried out on all
available cultures from 1996 to 2010 (n = 1933) at the Sanger
Institute, using the Illumina HiSeq 2000 system, with paired-end
reads of 100 base pairs. For each of the samples, Trimmomatic
software (http://www.usadellab.org/cms/?page=trimmomatic)
was used to remove low-quality sequences and low-quality 3′
ends of reads, retaining only reads at least 50 base pairs long,
with nucleotides above quality score Q27 (equivalent to a risk
of error of <0.2% per read per base pair). The trimmed sequence
reads for each sample were mapped against the H37Rv reference
genome (GenBank accession no. AL123456.3) and other pub-
licly available mycobacterial genomes, using the BWA-mem al-
gorithm (http://bio-bwa.sourceforge.net/). Samples (n = 79)
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were excluded if the best match was a non-tuberculous myco-
bacterium or if their average genomic coverage was <10-fold.
The average coverage of the remaining samples was high (me-
dian, 88-fold [range, 12–608-fold]; mean, 127-fold).
Single-nucleotide polymorphism (SNP) positions were identi-
ﬁed using SAMtools (http://samtools.sourceforge.net/). Sample
genotypes were called using the majority allele (minimum fre-
quency, 75%) in positions supported by at least 20-fold total cov-
erage; they were otherwise classiﬁed as missing. This strategy
ignores heterozygous calls. Samples with >15% missing genotype
calls were excluded, thereby removing those that may be contam-
inated, those containing mixed isolates, or those involving tech-
nical errors. Similarly, we excluded SNPs with >15% missing
genotypes and those in highly repetitive and variable regions
(eg, PE/PPE genes). In the ﬁnal analysis, 94% of the M. tubercu-
losis genome was analyzed for variants. The ﬁnal data set consists
of 1718 samples (89% of the original cultures) and 40 046 SNPs.
Raw sequence data are available from the European Nucleotide
Archive (accession numbers ERP000436 and ERP001072).
Spoligotyping was performed in silico using SpolPred [19].
Lineages were deﬁned from spoligotype families [20]. For sam-
ples with RFLP results but no whole-genome sequence data
available, lineage was deduced from spoligotypes of these spec-
imens or others with the same RFLP within the data set, as pre-
viously described [21].
Mixed Infections
To explore whether any of the apparent reinfections were ex-
plained by the presence of a mixed infection, the number of het-
erozygous positions was calculated. A position was classiﬁed as
heterozygous if >1 allele accounted for ≥30% of the reads (and
there were >30 reads).
Genomic Associations
To explore genomic associations with relapse, the genomes
from the index episode of all individuals with molecularly con-
ﬁrmed relapses were compared with those from patients who
were actively followed up and had no evidence of recurrence.
Our in-house implementation of the PhyC algorithm [22] was
used to explore associations showing evidence of positive selec-
tion, using a phylogenetic tree produced by RAxML [23]. Ge-
nome-wide association analysis for SNPs and annotated
protein coding genes was performed using R statistical software,
using logistic regression and including lineage as a covariate.
For each gene, the number of mutations was aggregated by
individual. A Bonferroni cutoff based on the number of inde-
pendent genes with SNPs (3689) suggested a multiple testing–
adjusted signiﬁcance threshold of 0.000014.
Epidemiological Analysis
Rates of laboratory-conﬁrmed recurrence were calculated from
the end of treatment to the end of June 2011. The time at risk
for recurrence was censored at the date of death, leaving the dis-
trict, or the ﬁrst recurrence of tuberculosis, whether conﬁrmed
or not (since those receiving treatment are not at risk). HIV sta-
tus was treated as a time-varying covariate for those who were
HIV negative or had an unknown HIV status during the ﬁrst
episode. The date of seroconversion was taken as halfway be-
tween the last negative test result (or the end of the ﬁrst episode
if the HIV status during that episode was unknown) and the
ﬁrst positive test result (or the date of ART initiation if this
was the ﬁrst evidence of HIV positivity). Calendar time and
age were also treated as time-varying covariates. Survival meth-
ods and Nelson-Aalen plots of cumulative rates were used. Rate
ratios were calculated using Poisson regression, stratifying by
time since the end of treatment. STATA 13 was used for all stat-
istical analyses. Risk factors for relapse and reinfection were ex-
amined separately.
RESULTS
Differentiating Relapse and Reinfection
After quality control, 1718 whole-genome sequences were avail-
able for analysis. These included some individuals with >1 sam-
ple from the same or different disease episode. For each of these
individuals, the ﬁrst and last sample were selected if there were
>2 samples available. This left 92 individuals with paired sam-
ples, including 66 with samples from different episodes of dis-
ease. The number of SNPs between each of the pairs is shown in
Figure 1. There is a clear gap, with pairs having a difference of
≤8 SNPs or >100 SNPs. RFLPs were available for both members
of 42 pairs. All pairs (7 of 7) with a difference of >100 SNPs had
different RFLPs. All pairs (35 of 35) with ≤8 SNPs different had
identical RFLPs (n = 28) or RFLPs that differed by only 1 band
(n = 7).
Figure 1. Number of single-nucleotide polymorphisms between pairs of
samples from individuals from the same episode of tuberculosis or from an
index episode and a recurrent episode.
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For the main analysis, only pairs from different episodes were
used. Recurrence was deﬁned as being due to relapse if there was
a difference of ≤10 SNPs and as due to reinfection if there was a
difference of >100 SNPs. For individuals with recurrent epi-
sodes with RFLP but no whole-genome sequencing data avail-
able, the RFLP data were used to deﬁne relapse and reinfection.
Relapses had identical patterns or differed by 1 band. Reinfec-
tions had completely different patterns.
In the whole data set, the number of heterozygous positions
was low for most samples, with a few having large numbers of
heterozygotes. From inspection of the plot of the number of
heterozygotes per sample (Supplementary Figure 1), a cutoff
of 140, the inﬂection point in the empirical distribution of the
data, was chosen to identify possible mixtures. None of the re-
infections had evidence of mixed infections in either episode of
disease. Two of the patients with subsequent relapse had
evidence of a mixed infection in the ﬁrst episode (679 and
945 heterozygous positions).
All further analysis was restricted to individuals who received
a diagnosis of laboratory-conﬁrmed tuberculosis between Janu-
ary 1996 and February 2010, who were normally resident in
Karonga district, and who had completed treatment. There
were 1535 such individuals (Figure 2). Information beyond
the end of treatment was available for 1471 (96%). Of these,
139 had laboratory-conﬁrmed recurrences, and 64 had uncon-
ﬁrmed recurrences. Of the conﬁrmed recurrences, 55 were due
to relapse (deﬁned on the basis of SNP data in 46 cases and
RFLP data in 9 cases), and 20 were due to reinfection (deﬁned
on the basis of SNP data in 14 cases and RFLP data in 6 cases);
64 were unclassiﬁed (no paired samples were available). The 64
Figure 2. Selection of patients. Abbreviations: RFLP, restriction fragment-length polymorphism data; WGS, whole-genome sequence data.
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unclassiﬁed recurrences were similar to those that could be clas-
siﬁed in terms of age, sex, HIV status, and year.
Recurrence
The rate of recurrence decreased by time since the end of
the index episode. There were 71 recurrences in the ﬁrst year,
for a rate of 5.4 recurrences/100 person-years at risk (95%
conﬁdence interval [CI], 4.3–6.8); 27 in the second year, for a
rate of 2.7/100 person-years at risk (95% CI, 1.8–3.9); and 41
after the second year, for a rate of 1.0/100 person-years at risk
(95% CI, .76–1.4). The factors associated with recurrence within
the ﬁrst 2 years and beyond are shown in Table 1, and the de-
velopment of recurrences, relapses, and reinfections over time
are shown in Figure 3. Almost all known relapses (51 of 55)
Table 1. Rate of Tuberculosis Recurrence, by Patient and Index Tuberculosis Episode Characteristics
Characteristic
Rate of Recurrence per 100 Person-Years at Risk
During the First 2 Years After the First 2 Years
All Recurrences
(Relapse,
Reinfection)
Person-Years
at Risk Rate (95% CI)
All Recurrences
(Relapse,
Reinfection)
Person-Years
at Risk Rate (95% CI)
Overall 98 (51, 8) 2311 4.2 (3.5–5.2) 41 (4, 12) 3995 1.0 (.76–1.4)
Age, y
<30 22 (13, 4) 671 3.3 (2.2–5.0) 7 (2, 0) 758 0.92 (.44–1.9)
30–39 35 (17, 2) 770 4.5 (3.3–6.3) 16 (0, 7) 1314 1.2 (.75–2.0)
40–49 19 (9, 0) 417 4.6 (2.9–7.1) 7 (1, 1) 803 0.80 (.38–1.7)
≥50 22 (12, 2) 452 4.9 (3.2–7.4) 11 (1, 4) 1051 1.0 (.58–1.9)
Sex
Female 43 (25, 6) 1246 3.5 (2.6–4.7) 28 (1, 7) 2116 1.1 (.72–1.6)
Male 55 (26, 2) 1065 5.2 (4.0–6.7) 18 (3, 5) 1879 0.96 (.60–1.5)
HIV status
Negative 35 (21, 0) 922 3.8 (2.7–5.3) 9 (1, 1) 1978 0.46 (.24–.87)
Positive 59 (29, 7) 1087 5.4 (4.2–7.0) 31 (3, 11) 1412 2.2 (1.5–3.1)
Unknown 4 (1, 1) 302 1.3 (.50–3.5) 1 (0, 0) 605 0.17 (.02–1.2)
Tuberculosis type
Smear-positive pulmonary 82 (47, 4) 1894 4.3 (3.5–5.4) 35 (3, 10) 3244 1.1 (.77–1.5)
Smear-negative pulmonary 13 (3, 3) 269 4.8 (2.8–8.3) 4 (1, 1) 440 0.91 (.34–2.4)
Extrapulmonary 3 (1, 1) 148 2.0 (.65–6.3) 2 (0, 1) 310 0.65 (.16–2.6)
Previous tuberculosis
No 90 (49, 7) 2167 4.2 (3.4–5.1) 38 (4, 11) 3759 1.0 (.74–1.4)
Yes 8 (2, 1) 144 5.5 (2.8–11.1) 3 (0, 1) 235 1.3 (.41–4.0)
M. tuberculosis lineage
1 11 (6, 1) 270 4.1 (2.3–7.4) 8 (0, 3) 468 1.7 (.85–3.4)
2 1 (1, 0) 70 1.4 (.20–10.1) 1 (0, 1) 156 0.64 (.09–4.5)
3 22 (16, 0) 167 13.2 (8.7–20.0) 1 (0, 0) 212 0.47 (.07–3.4)
4 41 (27, 6) 1192 3.4 (2.5–4.7) 25 (4, 8) 2158 1.2 (.78–1.7)
Unknown 23 (1, 1) 614 3.7 (2.5–5.6) 6 (0, 0) 1000 0.60 (.27–1.3)
Isoniazid resistance
No 76 (44, 8) 1843 4.1 (3.3–5.2) 33 (3, 9) 3344 1.0 (.70–1.4)
Yes 9 (6, 0) 81 11.1 (5.8–21.4) 4 (1, 3) 109 3.7 (1.4–9.8)
Unknown 13 (1, 0) 387 3.4 (2.0–5.8) 4 (0, 0) 542 0.74 (.28–2.0)
Year of follow-up
1996–2000 25 (11, 6) 589 4.2 (2.9–6.3) 3 (0, 1) 151 2.0 (.64–6.2)
2001–2004 26 (19, 2) 629 4.1 (2.8–6.1) 11 (2, 4) 1042 1.1 (.58–1.9)
2005 and later 47 (21, 0) 1093 4.3 (3.2–5.7) 27 (2, 7) 2802 0.96 (.66–1.4)
Year of treatment initiation
Before 2007 80 (47, 8) 1786 4.5 (3.6–5.6) 39 (4, 12) 3862 1.0 (.74–1.4)
2007 and later 18 (4, 0) 525 3.4 (2.2–5.4) 2 (0, 0) 132 1.5 (.38–6.0)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; M. tuberculosis, Mycobacterium tuberculosis.
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occurred in the ﬁrst 2 years, whereas reinfections occurred at a
more constant rate over time.
Relapse
Because of the very low number and rate of (conﬁrmed) relapses
after 2 years, risk factors for relapse were investigated within the
ﬁrst 2 years (Table 2). Relapses were more common soon after the
end of treatment. They were not associated with age, sex, or HIV
status. Fifty-ﬁve patients had strains that were isoniazid resistant
in the index episode (including 5 that were also rifampicin resis-
tant). Patients with isoniazid-resistant strains had 3 times the rate
of relapse of those who had isoniazid-susceptible strains. Those
who started treatment after 1 January 2007, who would have re-
ceived rifampicin throughout their treatment, had much lower
rates of relapse (rate ratio [RR], 0.29 [95% CI, .10–.80]). Those
with lineage-3 strains had much higher relapse rates than those
with strains from other lineages (RR, 4.2 [95% CI, 2.3–7.8], com-
pared with lineage-4). All of these associations persisted after ad-
justment for each other, and additional adjustment for the other
factors made no difference to the results (Table 2).
The genomes of isolates from the index tuberculosis episodes
of 52 patients with relapse were compared with those from 843
patients with active follow-up and no recurrence of tuberculosis.
An analysis of SNPs showing evidence of convergent evolution
and positive selection based on the PhyC algorithm found 9
SNPs (from 8 genes) that were signiﬁcant at the 5% level (Sup-
plementary Table 1). Six SNPs overlapped protein-coding genes
and caused nonsynonymous changes. These include the known
isoniazid-resistance associated gene, katG. Genome-wide asso-
ciation analyses showed no signiﬁcant genic results, after cor-
rection for multiple testing. Supplementary Table 2 lists all
genes identiﬁed at a less stringent threshold (P < .05); this in-
cludes katG.
Reinfection
The main factor associated with reinfection was HIV status
(Table 2). Among HIV-negative individuals, only 1 of 44 recur-
rences was due to reinfection, 22 were relapses, and 21 could not
be classiﬁed. Among HIV-positive individuals, 18 of 90 recur-
rences were due to reinfection, 32 were relapses, and 40 could
Figure 3. Cumulative hazard of conﬁrmed recurrent tuberculosis overall (A) and by human immunodeﬁciency virus (HIV) status (B ). C and D, Cumulative
hazard for recurrences due to relapse and reinfection, by HIV status.
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not be unclassiﬁed. The one HIV-negative patient with reinfec-
tion was conﬁrmed as being HIV negative at the time of the sec-
ond episode. Reinfections were less common in more recent
calendar years and were less common in the ﬁrst year after
the end of treatment than they were subsequently. These asso-
ciations became slightly stronger after adjustment for each
other, with no further change after adjustment for the other
available factors. Isoniazid resistance in the ﬁrst episode was
Table 2. Relative Rates for Relapse (Within 2 Years) and Reinfection (At Any Time)
Characteristic
Rate Ratio for Relapse Within 2
Years (95% CI)
P Valueb
Rate Ratio for Reinfection Disease
(95% CI)
P ValuebUnivariable Multivariablea Univariable Multivariablea
Age, y, at start
<30 1 . . . 1 . . .
30–39 1.1 (.55–2.3) . . . 1.5 (.48–5.0) . . .
40–49 1.1 (.48–2.6) . . . 0.28 (.03–2.5) . . .
≥50 1.4 (.63–3.0) . . . 1.4 (.40–5.1) . . .
Sex
Female 1 . . . 1 . . .
Male 1.2 (.70–2.1) . . . 0.61 (.25–1.5) . . .
HIV status
Negative 1 . . . 1 1 <.001c
Positive 1.2 (.67–2.1) . . . 20.9 (2.8–156) 21.0 (2.8–157)
Unknown 0.15 (.02–1.1) . . . 3.2 (.20–51.1) 2.5 (.15–40.2)
Tuberculosis type
Smear-positive pulmonary 1 . . . 1 . . .
Smear-negative pulmonary 0.45 (.14–1.4) . . . 2.1 (.68–6.3) . . .
Extrapulmonary 0.27 (.04–2.0) . . . 1.6 (.36–6.3) . . .
Previous tuberculosis
No 1 . . . 1 . . .
Yes 0.61 (.15–2.5) . . . 1.7 (.40–7.5) . . .
M. tuberculosis lineage
1 0.99 (.41–2.4) 1.0 (.42–2.4) .004c 1.3 (.43–3.9) . . .
2 0.63 (.09–4.6) 0.65 (.09–4.8) 1.1 (.14–8.0) . . .
3 4.2 (2.3–7.8) 4.2 (2.2–7.8) . . . . . .
4 1 1 1 . . .
Unknown 0.07 (.01–.53) 0.09 (.009–.87) 0.15 (.02–1.1) . . .
Isoniazid resistance
No 1 1 .05c 1 1 .06c
Yes 3.1 (1.3–7.3) 2.6 (1.1–6.0) 4.8 (1.4–16.5) 4.1 (1.2–14.0)
Unknown 0.11 (.01–.79) 0.91 (.09–9.1) . . . . . .
Calendar year
1996–2000 1 . . . 1 1 .001
2001–2004 1.6 (.77–3.4) . . . 0.38 (.13–1.1) 0.20 (.06–.66)
2005 and later 1.0 (.50–2.1) . . . 0.19 (.07–0.54) 0.10 (.03–.32)
Follow-up
First year 1 1 .002 1 1 .03
Second year 0.40 (.21–.77) 0.39 (.20–.74) 3.9 (.79–19.4) 4.7 (.94–23.3)
Third year and later . . . . . . 2.0 (.44–8.8) 5.9 (1.2–29.7)
Year of treatment initiation
Before 2007 1 . . . .006 . . . . . .
2007 and later 0.29 (.10–.80) 0.29 (.10–.83) . . . . . .
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; M. tuberculosis, Mycobacterium tuberculosis.
a Adjusted for the other factors shown in the multivariable model.
b From the likelihood ratio χ2 test.
c From the model excluding unknowns for this variable.
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also weakly associated with recurrence due to reinfection
(Table 2).
Of the 20 strains causing reinfection, 1 (5%) was lineage-1, 5
(25%) were lineage-2, 2 (10%) were lineage-3, and 12 (60%)
were lineage-4. This compares with a distribution of lineages
of 16%, 4%, 11%, and 68%, respectively, for the 4 lineages for
the index episode (P = .004, by the Fisher exact test). The pro-
portion of index episodes due to lineages 1 and 2 changed little
over the study, so this did not explain the difference. Of the 19
patients with reinfection for whom the lineage was known in
both episodes, 10 (53%) had different lineages in the 2 episodes
(compared with 48% expected by chance, given the lineage dis-
tribution in the population). For the 14 patients with reinfection
deﬁned on the basis of SNP data, the number of differing SNPs
was 100–200 for 4 patients, 600–800 for 2 patients, and >1000
for 8 patients. All those with <1000 differing SNPs had lineage-
4 strains in both episodes. All those with a difference of >1000
SNPs had different lineages in the 2 episodes. The one reinfec-
tion in an HIV-negative patient was with a lineage-2 strain, fol-
lowing lineage-1 in the initial episode.
DISCUSSION
Whole-genome sequencing of strains from initial and recurrent
episodes of disease showed a clear distinction between those
with few (0–8) different SNPs and those with many (>100) dif-
ferences. That this was an appropriate cutoff for distinguishing
relapse and reinfection is supported by the distribution of SNP
differences within the same episode (Figure 1), by the RFLP re-
sults, and by the strong correlation of relapse and reinfection so
deﬁned with time since the end of treatment and with HIV sta-
tus. The cutoff is slightly higher than suggested in some other
studies of SNP differences within the same episode or during
transmission between patients [24–26], but there is considerable
uncertainty about the appropriate cutoff, and the value will vary
depending on the pipeline used and the genome coverage
achieved [26]. The correlation between SNP and RFLP results
suggests that an RFLP that is identical or differs by 1 band is
a good approximation for deﬁning relapse when no sequencing
data are available.
In this study, none of the reinfections were explained by
mixed infection. This is in contrast to ﬁndings from Cape
Town, where the annual risk of infection with M. tuberculosis
is much higher [12, 27].We have previously found a low propor-
tion of mixed infections in this population [28].
The timing and risk factors for relapse and reinfection in this
population are strikingly different. Relapse was most common
in the ﬁrst year and rare after the second year. Recurrences
due to reinfection were less common in the ﬁrst year, but
then the rate was approximately constant. HIV infection greatly
increased the rate of recurrence due to reinfection but was not
associated with relapse. Calendar year was also associated with
recurrence due to reinfection, with higher rates before 2001,
when the incidence of new tuberculosis cases was also higher
[15].Relapse was associated with isoniazid resistance (as expect-
ed [29]), treatment in earlier years (before rifampicin was given
in the continuation phase, consistent with the reported effect of
prolonged rifampicin on recurrence [30]), and lineage.
There is increasing interest in the extent to which genomic
variation in M. tuberculosis may explain the variations seen in
disease occurrence, patterns, and outcomes. Several studies have
shown an increased rate of relapse for lineage-2 (Beijing) strains
[31–33]. We did not ﬁnd this, but there were only 43 patients
with lineage-2 strains in the index episode, so study power
was limited. We found greatly increased relapse rates for those
with lineage-3 strains (East African Indian/CAS), independent of
other factors. This has not been described before. In a recent
study from Vietnam [33], relapse rates were compared between
the Beijing strain and all other strains; lineage-3 made up about
half of the comparison group. Even if all of the relapses had oc-
curred in patients with this lineage, the rate would have been
lower than the rate for those with Beijing strains. Using the
PhyC algorithm and genome-wide association analysis, we
found no genomic variants strongly associated with relapse. The
expected ﬁnding of associations with katG, which is known to be
involved in isoniazid resistance, supports the validity of the meth-
ods and suggests that the other identiﬁed genes should be inves-
tigated further for clues for mechanisms for relapse.
Although this is one of the largest studies to compare paired
samples to differentiate relapse and reinfection, power is limited
for genetic comparisons of this type. The lack of paired samples
for 46% of the recurrences (64 of 139) will have led to underes-
timation of relapse and reinfection rates but is unlikely to have
biased the results of associations with relapse and reinfection, as
individuals without paired samples were similar to those with
paired samples.
In the only previous study to use whole-genome sequencing to
look at reinfection, it was suggested, based on 3 reinfections, that
reinfections with strains differing by >1000 SNPs (representing
different lineages) might be more likely [12]. In this analysis, 9
of 19 patients with reinfections with the lineage known for
both episodes had reinfections with the same lineage, which
does not support this hypothesis. However, there was some evi-
dence that the lineage of the reinfecting strain might be impor-
tant. Among episodes of recurrence due to reinfection, we found
that lineage-2 strains were overrepresented and that lineage-1
(Indo-Oceanic) strains were underrepresented. This strengthens
our earlier observations in this population [2] and is consistent
with suggested higher virulence for lineage-2 strains [34] and
lower virulence of lineage-1 strains [21]. Other studies of reinfec-
tion have not reported the results by lineage.
The use of whole-genome sequencing surmounts some of the
potential problems with older techniques, namely, excluding
mixed infections and knowing how much change to allow
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when comparing specimens from the different episodes of dis-
ease. It validated our earlier results with RFLP analysis [2] and
allows the genomic associations with relapse and reinfection to
be examined directly.
In this large population-based study with active follow-up,
relapses were rare after the ﬁrst 2 years and were associated with
drug resistance and lineage-3 genotypes. Reinfections occurred
at a more constant rate, were largely restricted to HIV-positive
individuals, and were not more likely to be due to different
lineages from the index episode but were due to lineage-2 geno-
types more often than would be expected by chance.
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